Pain and ketoprofen: What is its role in clinical practice?;Dolore e ketoprofene: Quale ruolo nella pratica clinica?

Reumatismo

Volumn 62, Issue 3, 2010, Pages 172-188

  Sarzi Puttini, P ^a   Atzeni, F ^a   Lanata, L ^b   Bagnasco, M ^b   Colombo, M ^c   Fischer, F ^c   D'Imporzano, M ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Chemistry Section   (Italy)

^c G Pini Orthopaedic Institute   (Italy)

Author keywords

Dolore post operatorio; Dolore reumatico; FANS; Ketoprofene; Ortopedico

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CELECOXIB; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ELASTOMER; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOPROFEN LYSINE; METHOTREXATE; MORPHINE; NALOXONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PETHIDINE; PLACEBO; STEROID;

ARTHRALGIA; BLEEDING; BLOOD CLOTTING PARAMETERS; BURSITIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONTUSION; DEVICE THERAPY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EPICONDYLITIS; GOUT; HUMAN; HYPERCAPNIA; HYPERTENSION; JOINT STIFFNESS; LOW BACK PAIN; MUSCULOSKELETAL SYSTEM MALFORMATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PERIARTHRITIS; POSTOPERATIVE PAIN; PROTHROMBIN TIME; PRURITUS; RESPIRATION DEPRESSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; SIDE EFFECT; SOFT TISSUE DISEASE; SOFT TISSUE INJURY; SPORT INJURY; SPRAIN; TENDINITIS; TENOSYNOVITIS; URINE RETENTION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CALCINOSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; GOUT; HUMANS; HYPERALGESIA; KETOPROFEN; OSTEOARTHRITIS; PAIN; PAIN PERCEPTION; PAIN, POSTOPERATIVE; POSTOPERATIVE COMPLICATIONS; SOFT TISSUE INJURIES;

EID: 78249290246     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Colvin LA, Lambert DG. Pain medicine: advances in basic sciences and clinical practice. Br J Anaesth 2008; 101: 1-4.
2. Merskey H, Bogduk N (Eds). Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed. Seattle: IASP Press, 1994.
3. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain 1993; 52: 157-68.
4. Turk DC, Wilson HD. Fear of pain as a prognostic factor in chronic pain: conceptual models, assessment, and treatment implications. Curr Pain Headache Rep. 2010; 14: 88-95.
5. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009; 10: 1187-204.
6. Brennan F, Carr BD, Cousins M. Pain Management: A Fundamental Human Right. Anesth Analg 2007; 105: 205-21.
7. The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. JAMA 1995; 274: 1591-8.
8. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management. I. Evidence from published data. Br J Anaesth 2002; 89: 409-23.
9. Powell AE, Davies HT, Bannister J, Macrae WA. Rhetoric and reality on acute pain services in the UK: a national postal questionnaire survey. Br J Anaesth 2004; 92: 689-93.
10. Manchikanti L, Singh V, Bakhit CE, Fellows B. Interventional techniques in the management of chronic pain: Part 1.0. Pain Physician. 2000; 3: 7-42.
11. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms and treatment. Lancet Neurol 2010; 9: 807-19.
12. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339-56.
13. Vlaeyen JW, Crombez G. Fear of movement/(re)injury, avoidance and pain disability in chronic low back pain patients. Man Ther 1999; 4:187-195.
14. Meeus M, Nijs J. Central sensitization: a biopsy-chosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007; 26: 465-73.
15. Staud R. Evidence of involvement of central neural mechanisms in generating FM pain. Curr Rheumatol Rep 2002; 4: 299-305.
16. Leung L, Cahill CM. TNF-a and neuropathic pain - a review. J Neuroinflammation 2010; 7: 27.
17. Ji R, Gereau RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009; 60: 135-48.
18. Bradesi S. Role of spinal cord glia in the central processing of peripheral pain perception. Neurogastroenterol Motil. 2010; 22: 499-511.
19. Roditi D, Waxenberg L, Robinson ME. Frequency and perceived effectiveness of coping define important subgroups of patients with chronic pain. Clin J Pain 2010; 26: 677-82.
20. McCormack KJ, Brune K. Dissociation between the anti-nociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs: a survey of their analgesic efficacy. Drugs 1991; 41: 533-47.
21. Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet 2001; 40: 245-62.
22. Cabré F, Fernández MF, Calvo L, Ferrer X, García ML, Mauleón D. Analgesic, antiinflammatory, and antipyretic effects of S(+)-ketoprofen in vivo. J Clin Pharmacol 1998; 38: 3S-10S.
23. Panerai A. [Symptoms of pain] Torino: Edizioni Minerva Medica, 1999.
24. Marmo E, Ottavo R, Giordano L, Paone G, Falcone O, Spaziante G, et al. Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, anti-inflammatory activity, anti-platelet aggregation activity and inter-ference with the biosynthesis of prostaglandins. Torino, Arch Sci Med 1980; 137: 387-404.
25. Natale, et al. Studio in soggetti volontari sani della biodisponibilità relativa e della farmacocinetica di ketoprofen dopo somministrazione per via orale sot-to forma di sale di lisina in formulazione bustine di granulato (dose singola e ripetuta) e in forma di ke-toprofen acido formulato in capsule. Data on file 1991.
26. ®) after oral administration to healthy volunteers of both sexes. (IPAS-KETO-025-94), data on file 1994.
27. D'arienzo M. Pennisi M, Zanolo G, Borsa M. Keto-profen lysine: ketoprofen serum levels and analgesic activity. Drugs Exp Clin Res 1984; 10: 863-6.
28. Veys EM. 20 Years' Experience with ketoprofen. Scan J Rheumatol 1991; 90: 3-44.
29. Walker JL. Interrelationships of SRS-A production and arachidonic acid metabolism in human lung tis-sue. Adv Prostaglandin Thromboxane Res 1980; 6: 115-9.
30. Díaz-Reval MI, Ventura-Martínez R, Déciga-Campos M, Terrón JA, Cabré F, López-Muñoz FJ. Evidence for a central mechanism of action of S-(+)-ke-toprofen. Eur J Pharmacol 2004; 483: 241-8.
31. Björkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995; 103: 1-44.
32. Ossipov MH, Jerussi TP, Ren K, Sun H, Porreca F. Differential effects of spinal (R)-ketoprofen and (S)-ketoprofen against signs of neuropathic pain and tonic nociception: evidence for a novel mechanism of action of (R)-ketoprofen against tactile allodynia. Pain 2000; 87: 193-9.
33. Kokki H, Karvinen M, Jekunen A. Diffusion of keto-profen into the cerebrospinal fluid of young children. Paediatr Anaesth 2002; 12: 313-6.
34. Kubota T, Komatsu H, Kawamoto H, Yamada T. Studies on the effects of anti-inflammatory action of ben-zoyl-hydrotropic acid (ketoprofen) and other drugs, with special reference to prostaglandin synthesis. Arch Int Pharmacodyn Ther 1979; 237: 169-76.
35. Kantor TG. Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy 1986; 6: 93-103.
36. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet 2005; 365: 965-73.
37. Carrabba M, Sarzi-Puttini P. Osteoarthritis in the third millennium: a new era for an old disease? Seminars Arthritis Rheum 2005; 34: 1-2.
38. Pritzker K. Pathology of osteoarthritis. In: Brandt K, Doherty M, Lohmander LS, eds. Osteoarthritis, 2nd edn. Oxford: Oxford University Press, 2003: 49-58.
39. Watt I, Doherty M. Plain radiographic features of osteoarthritis. In: Brandt K, Doherty M, Lohmander LS, eds. Osteoarthritis, 2nd edn. Oxford: Oxford University Press, 2003: 211-25.
40. Linaker CH, Walker-Bone K, Palmer K, Cooper C. Frequency and impact of regional musculoskeletal disorders. Baillieres Best Pract Res Clin Rheumatol 1999; 13: 197-215.
41. McCrae F, Shouls J, Dieppe P, Watt I. Scintigraphic assessment of osteoarthritis of the knee joint. Ann Rheum Dis 1992; 51: 938-42.
42. Creamer P, Hunt M, Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anes-thetic. J Rheumatol 1996; 23: 1031-6.
43. Farrell M, Gibson S, McMeeken J, Helme R. Pain and hyperalgesia in osteoarthritis of the hands. J Rheumatol 2000; 27: 441-7.
44. Marcolongo R, Canesi B, Ferri S, Oriente P, Perpignano G, Serni U, et al. Efficacy and tolerability of ke-toprofen 200 mg controlled-release cps vs in-domethacin 50 mg cps in patients with symptomatic hip osteoarthritis. A multicentre study. Minerva Med 1997; 88: 383-91.
45. Chevallard M, Mele G, Borsa M, Malandrino S, Tonon GC, Carrabba M. Effectiveness and tolerabil-ity of ketoprofen lysine, a once a day, in patients with rheumatic disorders. Drugs Exptl Clin Res 1987; 13: 293-6.
46. Torri G, Cecchettin M, Bellometti S, Galzigna L. Analgesic effect and beta-endorphin and substance P levels in plasma after short-term administration of a ketoprofen-lysine salt or acetylsalicylic acid in patients with osteoarthrosis. Curr Ther Res 1995; 56: 62-9.
47. Sarzi-Puttini P, Atzeni F. Rheumatoid arthritis from the clinical perspective. Reumatismo 2004; 3: 22-5.
48. Combe R. Early rheumatoid arthritis: strategies for prevention and management. Best Practice & Research Clinical Rheumatology 2007; 21: 27-42.
49. Guillemin F, Suurmeijer T, Krol B, Bombardier C, Briançon S, Doeglas D, et al. Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 1994; 21: 1051-5.
50. Wienecke T, Gotzsche PC. Paracetamol versus non-steroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004; 1: CD003789.
51. Carrabba M, Chevallard M, Mele G, Borsa M, Malandrino S, Tonon GC. Ketoprofen lysine in rheumatoid arthritis: efficacy and tolerability of two therapeutic schedules with evaluation of synovial prostaglandin levels. Current Ther Res 1987; 42: 70-6.
52. Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol 1991; 91: 27-36.
53. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol 1991; 18: 21-7.
54. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthri-tis Rheum 2004; 50: 2400-14.
55. Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout drugs. 2006; 66: 1547-63.
56. Richette P, Bardin T. Gout. Lancet 2010; 375: 318-28.
57. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3: 443-9.
58. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR Standing Committee for International Clinical Studies Including Ther-apeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24.
59. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331-4.
60. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database Syst Rev 2006; 4: CD006190.
61. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and pre-vention of recurrent gout - a systematic review. Rheumatology (Oxford) 2006; 45: 1422-31.
62. Siegmuth W, Placheta O. Double-blind trial: keto-profen versus phenylbutazone in acute gouty arthritis (German). Wien Klin Wochenschr 1976; 88: 535-9.
63. Cobra CJ, Cobra J. Comparative study of ketoprofen and penylbutazone in gout attacks (French). Ruma-tologie; 1980; 47: 141-6.
64. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422-6.
65. Biundo JJ Jr, Mipro RC Jr, Fahey P. Sports-related and other soft-tissue injuries, tendinitis, bursitis, and occupation-related syndromes. Curr Opin Rheumatol 1997; 9: 151-4.
66. Biundo JJ, Irwin RW, Umpierre E. Sports and other soft tissue injuries, tendinitis, bursitis, and occupation-related syndromes. Curr Opin Rheumatol 2001; 13: 146-9.
67. Wilson JJ, Best TM. Common overuse tendon problems: A review and recommendations for treatment. Am Fam Physician 2005; 72: 811-8.
68. Fatti, et al. Valutazione dell'efficacia e tollerabilità di ketoprofen sale di lisina in formulazione in bustine per uso orale in pazienti con affezioni flogistiche dell'ap-parato muscolo-scheletrico (Reumatismo extra-articolare) studio doppio cieco comparativo a placebo. Data on file, 1991. Evaluation of the effectiveness and tolerability of ketoprofen lysine salt formulation in sachets for oral use in patients with inflammatory diseases of the musculo-skeletal system (extra-artic-ular rheumatism), double-blind study compared with placebo.
69. Jokhio IA, Siddiqui KA, Waraich T, Abbas M, Ali A. Study of efficacy and tolerance of ketoprofen and di-clofenac sodium in the treatment of acute rheumatic and traumatic conditions. J Pak Med Assoc 1998; 48: 373-6.
70. Robbins D, Taylor MAH, Brown MD, McIlwain H. Ketoprofen versus ibuprofen for acute sports injuries: are there differences between nonsteroidal anti-in-flammatory drugs? Curr Ther Res 1990; 48: 780-9.
71. Chou R. Pharmacological management of low back pain. Drugs 2010; 70: 387-402.
72. Chou R. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the american col-lege of physicians and the american pain society. Ann Intern Med. 2007; 147: 478-91.
73. Van Tulder. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15: S169-91.
74. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976) 2008; 33: 1766-74.
75. Levernieux J, Beaslay N, Seze S. Comparative study between injectable ketoprofen and indometacine in the treatment of lomboradicular pain. Revue Internationale de rhumatologie 1986; 16: 171-5.
76. Matsumo S, Kaneda K, Norhara Y. Clinical evaluation of ketoprofen (Orudis) in lumbago - a double-blind comparison with diclofenac sodium. Br J Clin Pract 1981; 35: 266.
77. Castagnera L, Vital JM, Macouillard G, Destribats B, Esposito J, Harrewyn JM. Study of the analgesic ef-fectiveness of intravenous ketoprofen in orthopedic surgery. Sem Hop Paris 1988; 32: 2179-82.
78. Manani G, Corliano L, Zanette G, Pizzali M, Borreggine D, Calzigna L. Ketoprofen and Naproxen in acute postoperative orthopedic pain. Acta Anaesth Italica 1993; 44: 73-80.
79. Shah S, Soomro M, Kella U, Talpur A, Dino Dal W. Comparative study of non steroidal anti inflammatory drugs in postoperative pain. J Surg Pak Dec 2003; 8: 2-5.
80. Karvonen S, Salomaki T, Olkkola T. Efficacy of oral Paracetamol and Ketoprofen for pain management after measure orthopedic surgery. Methods Find Exp Clin Pharmacol 2008; 30: 703-6.
81. Anacardio R, Bartolini S, Gentile MM, Bagnasco M, Carlucci G. HPLC investigated physicochemical com-patibility between Artrosilene injectable solution and other pharmaceutical products frequently used for combined therapy into elastomeric Baxter LV5 infu-sion devices. Int J Immunopathol Pharmacol 2005; 18: 791-8.
82. Langlais F, Bourgin T, Maignan JM, Sauvage J, Harrewyn JM. Comparative study of ketoprofen and pethidine in severe postoperative pain. Ann Fr Anesth Reanim 1987; 6: 408-12.
83. Hommeril JL, Bernard JM, Gouin F, Pinaud M. Ketoprofen for pain after hip and knee arthroplasty. Br J Anaesth 1994; 72: 383-7.
84. Vastel L, Rosencher N, Siney H, Courpied JP. Prevention of heterotopic ossifications in hip arthroplas-ty: effectiveness of selective Cox-2 inhibitors (cele-coxib) versus ketoprofen. Rev Chir Orthop Reparatrice Appar Mot 2005; 91: 64-9.
85. Fiorentino S, Melillo G, Fedele G, Clavenna G, D'Agostino C, Mainetti E, et al. Ketoprofen lysine salt in-hibits disuse-induced osteopenia in a new non-trau-matic immobilization model in the rat. Pharmacol Res 1996; 33: 277-81.
86. Martins MV, da Silva MA, Medici Filho E, de Moraes LC, Castilho JC, da Rocha RF. Evaluation of digital optical density of bone repair in rats medicated with ketoprofen. Braz Dent J 2005; 16: 207-12.
87. Matsumoto MA, De Oliveira A, Ribeiro Junior PD, Nary Filho H, Ribeiro DA. Short-term administration of non-selective and selective COX-2 NSAIDs do not interfere with bone repair in rats. J Mol Histol 2008; 39: 381-7.
88. van der Heide HJ, Hannink G, Buma P, Schreurs BW. No effect of ketoprofen and meloxicam on bone graft ingrowth: a bone chamber study in goats. Acta Orthop 2008; 79: 548-54.
89. Urrutia J, Mardones R, Quezada F. The effect of ketoprophen on lumbar spinal fusion healing in a rabbit model. Laboratory investigation. J Neurosurg Spine 2007; 7: 631-6.
90. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by tra-ditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
91. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
92. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
93. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995; 142: 288-94.
94. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
95. McElnay JC, D'Arcy PF. Displacement of albumin-bound warfarin by anti-inflammatory agents in vitro. J Pharm Pharmacol 1980; 32: 709-11.
96. Sancilio LF, Taylor MA, Mathur PP, Crowe JT. In-teraction between warfarin and nonsteroidal anti-in-flammatory drugs (NSAIDs) in rats. Life Sci 1985; 36: 1041-50.
97. Mieszczak C, Winther K. Lack of interaction of ke-toprofen with warfarin. Eur J Clin Pharmacol 1993; 44: 205-6.
98. Saran T, Sodolski W, Sodolska K, Danilkiewicz WC, Schabowski J. Effect of nimesulide-a preferential COX-2 inhibitor on arterial blood pressure, compared to ketoprofen. Ann Univ Mariae Curie Sklodowska Med 2004; 59: 261-7.
99. Weiss Y, Chenard A, De Kermadec JM, Tertrain F, Abiteboul M. Maintenance of blood pressure control in elderly hypertensives on ketoprofen. Scand J Rheumatol Suppl 1991; 91: 37-44.
100. Cusson JR, du Souich P, Le Morvan P, Thibault G, Phillips R, Milot A, et al. Effect of ketoprofen on blood pressure, endocrine and renal responses to chronic dosing with captopril in patients with essential hypertension. Blood Press 1992; 1: 162-7.
101. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systemic review of the selective and nonselective inhibitors of cyclooxygenase. JAMA 2006; 296: 1633-44.
102. Ray WA, Stein CM, Hall K. Daugherty JR, Griffin MR. Non steroidal anti-inflammatory drugs and risk of serious coronary heart disease; an observational cohort. Lancet 2002; 359: 118-23.
103. Andersohn F. Use of first and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950-7.
104. Singh G, Wu O, Ranghorne P, Madhok R. Risk of acute myocardial infarction with non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006; 8: 153-8.
105. Jakovljevic V, Sabo A, Tomić Z, Milijasević B, Popovic M, Vasovic V, et al. Interaction of diclofenac and ketoprofen with cardioactive drugs in rats. Eur J Drug Metab Pharmacokinet 2009; 34: 11-7.